Floatz logo

SOMATOSTATIN

Hypoglycaemia

Cambridge University Hospitals NHS Foundation Trustprotein_peptideN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hypoglycaemia cohort.

Asset / SponsorPhaseRating
Liraglutide
Zealand University Hospital
Phase 4BB
VERAPAMIL SLOW RELEASE
Zealand University Hospital
Phase 4BB
Sitagliptin
Zealand University Hospital
Phase 4BB
Empagliflozin
Insel Gruppe AG, University Hospital Bern
Phase 4BB
Acarbose
Zealand University Hospital
Phase 4BB

View all 10 →

Same molecule, other indications

SOMATOSTATIN is also rated in:

upper digestive tract disorderDormant
BB
Indicative ·
69 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative ·
67 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →